Venus Concept (NASDAQ:VERO) Earns Sell (E+) Rating from Weiss Ratings

Venus Concept (NASDAQ:VERO)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Venus Concept Trading Down 7.1%

NASDAQ:VERO opened at $2.50 on Wednesday. Venus Concept has a 1-year low of $2.10 and a 1-year high of $14.50. The business’s 50-day moving average price is $2.36 and its two-hundred day moving average price is $2.60. The company has a current ratio of 1.10, a quick ratio of 0.71 and a debt-to-equity ratio of 5.72. The firm has a market capitalization of $3.55 million, a price-to-earnings ratio of -0.05 and a beta of 0.05.

Venus Concept (NASDAQ:VERO) last released its earnings results on Thursday, August 14th. The company reported ($8.03) earnings per share for the quarter, beating the consensus estimate of ($9.72) by $1.69. Venus Concept had a negative return on equity of 871.77% and a negative net margin of 68.77%.The firm had revenue of $15.69 million for the quarter, compared to analyst estimates of $14.01 million.

About Venus Concept

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.